4.7 Article

A retinoic acid receptor beta agonist (CD2019) overcomes inhibition of axonal outgrowth via phosphoinositide 3-kinase signalling in the injured adult spinal cord

Journal

NEUROBIOLOGY OF DISEASE
Volume 37, Issue 1, Pages 147-155

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.nbd.2009.09.018

Keywords

-

Categories

Funding

  1. Wellcome Trust

Ask authors/readers for more resources

After spinal cord injury in the adult mammal, axons do not normally regrow and this commonly leads to paralysis. Retinoic acid (RA) can stimulate neurite outgrowth in vitro of both the embryonic central and peripheral nervous system. via activation of the retinoic acid receptor (RAR) beta 2 We show here that regions of the adult CNS. including the cerebellum and cerebral cortex, express RAR beta 2. We show that when cerebellar neurons are grown in the presence of myelin-associated glycoprotein (MAC) which inhibits neurite outgrowth, RAR beta can be activated in a dose dependent manner by a RAR beta agonist (CD2019) and neurite outgrowth can occur via phosphoinositide 3-kinase (PI3K) signalling. In a model of spinal cord injury CD2019 also acts through PI3K signalling to induce axonal outgrowth of descending corticospinal fibres and promote functional recovery Our data suggest that RAR beta agonists may be of therapeutic potential for human spinal cord injuries. (C) 2009 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available